Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07300943 · ClinicalTrials.gov registry record · Phase 1

Study in Advanced Solid Tumor Patients

A Phase 1 study of Advanced Solid Tumor, sponsored by Callio Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
306
Enrollment target
11
Study locations

NCT07300943 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Callio Therapeutics. The registered enrollment target is 306 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (60% higher). The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07300943, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Callio Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
306 participants
Enrollment target
11
Study locations

Study Summary

The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumor-specific expansion cohorts to optimize dosing and assess preliminary efficacy.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG CLIO-8221

Study Locations (11)

Victoria

  • Peter Maccallum Cancer Centre - Box Hill
  • AlfredHealth - Heidelberg
  • Royal Melbourne Hospital - Melbourne

Texas

  • MD Anderson Cancer Center - Houston
  • START San Antonio - San Antonio

Massachusetts

  • DFCI - Boston

Tennessee

  • Sarah Cannon Research Institute 335 24th Avenue North, Suite 400 - Nashville

Utah

  • START Mountain - West Valley City

New South Wales

  • Scientia Clinical Research - Randwick

Queensland

  • Integrated Clinical Oncology Network Pty Ltd - South Brisbane

Western Australia

  • Linear Clinical Research Ltd - Nedlands

Trial Details

FieldValue
Enrollment Target 306 participants
Start Date 2026-02-28
Est. Completion 2028-07-17
Phase Phase 1

Sponsor

Callio Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07300943

The ClinicalTrials.gov registry entry for NCT07300943 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (60% higher). The listed sponsor is Callio Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which CLIO-8221 is the first listed.

NCT07300943 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Victoria, Texas, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07300943 about?

NCT07300943 is a clinical study titled "Study in Advanced Solid Tumor Patients". The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumor...

What is the current status of trial NCT07300943?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 306 participants. The study started on 2026-02-28. Estimated completion is 2028-07-17.

What conditions does trial NCT07300943 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT07300943?

The interventions under investigation include: CLIO-8221 (DRUG).

Who is sponsoring clinical trial NCT07300943?

This trial is sponsored by Callio Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07300943 being conducted?

This trial has 11 study locations across Massachusetts, Tennessee, Texas, Utah, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.